Introduction
The vertebrate retina is a laminar structure composed of seven cell types, all derived from a common pool of multipotent retinal progenitor cells (RPCs) Cayouette et al., 2006; Bassett and Wallace, 2012) . Retinogenesis follows an evolutionarily conserved, but overlapping, sequence with retinal ganglion cells (RGCs), amacrine cells (ACs), horizontal cells (HCs), and cone photoreceptors becoming postmitotic first, whereas rod photoreceptors, bipolar cells, and Müller glial cells are generated during a later wave of differentiation (Young, 1985; Rapaport et al., 2004) . This sequence depends on both cellextrinsic and cell-intrinsic factors Cayouette et al., 2006; Bassett and Wallace, 2012) which determine both distinct and successive cell-fate choice by RPCs. Several converging lines of evidence point to specific transcription factors (homeoproteins, basic helix-loop-helix, forkhead/winged helix, basic motif-leucine zipper, etc.) as intrinsic retinogenic factors (Furukawa et al., 1997; Hatakeyama et al., 2001; Mears et al., 2001; Dyer et al., 2003; Li et al., 2004; Matter-Sadzinski et al., 2005; Fujitani et al., 2006; Jia et al., 2009; Swaroop et al., 2010 ). An increasing number of data indicates that post-transcriptional regulation at the mRNA level, such as alternative splicing regulation, RNA-binding proteins (Boy et al., 2004) , and noncoding RNA processing (Decembrini et al., 2009; Georgi and Reh, 2010; Hwang et al., 2012; Maiorano and Hindges, 2012 ) also play a key role in retinal development.
Several transcriptomic analyses during rat retinal development, enabled us to identify a novel transcription factor in retinal development, namely Bcl-2-associated transcription factor 1 (Bclaf1; Roger et al., 2007) . Although it was originally identified as a protein interacting with antiapoptotic members of the Bcl-2 family (Kasof et al., 1999), Bclaf1 actually does not share structural similarities with these proteins. The most prominent feature of the Bclaf1 sequence is the presence of an arginine-serine rich (RS) domain typically found in proteins involved in pre-mRNA splicing or mRNA processing and of two distinct domains, respectively homologous to the bZIP and to the Myb DNA-binding domains (Kasof et al., 1999; Haraguchi et al., 2004) . In vitro studies have also implicated Bclaf1 in pathways that link transcriptional events to cell death, autophagy or DNA repair (Haraguchi et al., 2004; Liu et al., 2007; Rénert et al., 2009; Sarras et al., 2010; Lamy et al., 2013) . However, several lines of evidence indicate that Bclaf1 has a much broader function and serves in various processes that are not typically related to Bcl-2 function (McPherson et al., 2009; Sarras et al., 2010) . For instance, Bclaf1 participates in processes that regulate RNA metabolism (Merz et al., 2007; Bracken et al., 2008; Sarras et al., 2010) and studies conducted in Bclaf1-deficient mice revealed new functions of Bclaf1 in peripheral T-cell homeostasis and proper lung development (McPherson et al., 2009) . In this study, we report a new function for Bclaf1 in retinal development during which Bclaf1 participates in regulating the differentiation of early-born retinal cells independently of interactions with Bcl-2-related proteins.
Materials and Methods
Animals. Timed pregnant C57BL/6J mice and Sprague-Dawley OFA were purchased from Charles River Laboratories. Bclaf1-deficient mice maintained in a C57BL/6J background have been described previously (McPherson et al., 2009 ). Embryos were obtained by mating Bclaf1 heterozygote animals and were genotyped as previously described (McPherson et al., 2009 ). The day of vaginal plug corresponded to embryonic day (E)0, and the day of birth corresponded to postnatal day (P)0. Animals were killed according to the recommendations of our local ethical and animal care committee and eyes were dissected to recover neural retinal tissues (Authorization 75-865 delivered on April 30, 2010 by the Minister of Agriculture). The methods used to secure animal tissue complied with the Association for Research in Vision Ophthalmology Statement for the Use of Animals in Ophthalmic and Vision Research.
Retinal explants cultures and electroporation. Retina used for explants cultures were dissected in CO 2 -independent medium (Life Technologies) and the central regions of the retinas were placed on polycarbonate filter discs (Dutscher). Cultures were maintained up to 7 d in DMEM/ F12 medium with 10 mM HEPES, pH 7.0 containing 5% fetal calf serum and 100 g/ml penicillin-streptomycin (Life Technologies), and half of medium was changed every 3 d.
For electroporation, the central regions of retinas from embryos (E16) and newborn (P0) pups were dissected and submerged in 1 mg/ml DNA as previously described (Roger et al., 2006) . The retinas were oriented so that outer layer of the retina was facing the negative electrode. They were then subjected to five electric pulses at 30 V with 50 ms duration and 950 ms intervals using a CUY21 electroporator (CUY21 Single Cell BEX; Nepa Gene, Sonidel) using bath platinum plate electrodes on Petri dishes (CUY520P5, Nepa Gene). Explants were then placed on polycarbonate filter discs (Dutscher) and cultured as described above.
Cryosection and cell dissociation. For cryosectioning, retinal explants or dissected eyes were fixed for 30 min (explants) or 1-2 h (according to the developmental stage) in cold 4% paraformaldehyde (PFA) at 4°C and incubated in PBS, 30% sucrose (Sigma-Aldrich) 1 h (explants) or overnight (eyes) followed by an incubation at 37°C in PGS (PBS, 7.5% gelatin, Sigma-Aldrich; 10% sucrose) for 1 h. Eyes were embedded in PGS and frozen at Ϫ50°C in isopentane. Fourteen-micrometer-thick cryosections were collected. For cell dissociation, explants were detached from their filters and dissociated with trypsin as previously described (Roger et al., 2006) . Dissociated cells were plated on glass slides coated with poly-Dlysine at 37°C for 2-3 h before fixation in cold 4% PFA for 10 min and immunostaining.
Immunostaining and image acquisition. Immunofluorescence staining of retinal sections or dissociated cells was performed as previously described (Roger et al., 2006) . Briefly, slides were incubated for 1 h at room temperature with blocking solution (PBS containing 0.2% gelatin, and 0.1-0.5% Triton X-100) and then with the primary antibody overnight at 4°C. The following primary antibodies were used: mouse anti-AP2 (DSHB), mouse anti-Brn3a (Millipore), mouse and rabbit anti-Bclaf1 (BD Biosciences and Bethyl), rabbit anti-Calbindin (Swant), mouse antiCalretinin (Millipore), rabbit anti-Cone arrestin (CAR; Millipore), mouse anti-CyclinD1 (Santa Cruz Biotechnology), mouse and rabbit anti-GFP (Roche and Clinisciences), mouse anti-glutamine synthetase (GS; Millipore), mouse anti-Lim1 (DSHB); rabbit anti-Otx2 (Millipore), rabbit anti-Pax6 (Millipore), rabbit anti-proliferating cell nuclear antigen (PCNA; Santa Cruz Biotechnology) rabbit anti-Protein Kinase C␣ (PKC␣, Santa Cruz Biotechnology), mouse anti-rhodopsin (R4D2, gift from Dr Molday, University of British Columbia, Vancouver, Canada), rabbit anti-recoverin (Millipore), rabbit anti-Retinoid acid receptor gamma (RXR␥; Santa Cruz Biotechnology), and rabbit anti-Sox9 (Millipore). Slides were washed three times in PBS with Tween 0.1% and then incubated for 1 h with appropriate secondary antibody conjugated with AlexaFluor 488 or 594 diluted at 1:500 in blocking buffer with 1:1000 diamidino-phenyl-indole (DAPI). TUNEL assays were performed using the in situ cell death detection kit (Roche Diagnostics) according to the manufacturer's recommendations. Fluorescent staining signals were captured with a DM6000 microscope (Leica Microsystems) equipped with a CCD CoolSNAPfx monochrome camera (Roper Scientific) or with an Olympus FV1000 confocal microscope equipped with 405, 488, and 559 nm lasers. Confocal images were acquired using a 0.52 m step size and each image corresponds to the projection of 4 -8 optical sections. MetaMorph software (Universal Imaging) was used to measure and analyze the intensity of fluorescent staining after cell dissociation of electroplated retinal explants. The same thresholds for fluorescent staining signals were used for a given antibody combination and experiment. For cell quantifications, retinal sections were scanned at high resolution (0.23 m/pixel) with the Hamamatsu Nanozoomer Digital Pathology (NDP) 2.0 HT (fluorescence unit L11600-05) and the NanoZoomer's 3-CCD TDI camera (Hamamatsu Photonics). Quantifications were performed using the NDP viewer1.2.47 software with the NDPviewEx1.3.8 counter unit.
RT-PCR and quantitative-PCR. mRNA was prepared using a Nucleospin RNA II kit (Macherey Nagel) and cDNA synthesis was performed using the SuperScript II Reverse Transcriptase (Life Technologies), each according to the suppliers instructions. For cell sorting, a total of 10 5 cells GFP-positive dissociated cells were collected in lysis buffer (Nucleospin RNA II) using Vantage Sorter (BD Biosciences). PCR were performed in 25 l final volume with TaqDNA polymerase (Life Technologies) and 10 M of each forward and reverse primers (primers used for the identification of the isoforms of Bclaf1: a forward 5Ј-CCCGGCTAGCAGGAGAG-GAGA-3Ј; b reverse 5Ј-CTATTCCTTTTCTTCTTTGCGT-3Ј; and c forward 5Ј-GAGGAACCTTTCGATGACAGAG-3Ј) according to the manufacturer's instructions. Cycling protocol was as follows: 95°C, 2 min; 32 cycles of 95°C, 30 s; 68°C, 30 s; and 72°C, 45 s, followed by a final extension step at 72°C for 5 min. PCR products were run on a 1.5% agarose gel stained with ethidium bromide and visualized under UV illumination.
For quantitative PCR, reactions were performed in a 20 l final volume with Power SYBR Green PCR Master Mix (Life Technologies) and 0.25 M primers (Atoh7 forward 5Ј-ATGGCGCTCAGCTA CATCATC-3Ј and reverse 5Ј-CATAGGGCTCAGGGTCTACCT-3Ј; Ascl1a forward 5Ј-GCAACCGGGTCAAGTTGGT-3Ј and reverse 5Ј-GTCGTTGGAGTAGTTGGGGG-3Ј; Bclaf1 forward 5Ј-AAAGAGCCC TGAGATACACA-3Ј and reverse 5Ј-CTTCTTTAAAAACTCTCT CGT-3Ј; FoxN4 forward 5Ј-GAAAGCTTCAGCCTGGACAC-3Ј and reverse 5Ј-TAGGCCGCATAGAGACCTGT-3Ј; Ngn2 forward 5Ј-TCG-GCTTTAACTGGAGTGCC-3Ј and reverse 5Ј-GTGTGTTGTCG TTCTCGTGC-3Ј; Ptf1a forward 5Ј-CTACGGTCTCCCTCCTCT TG-3Ј and reverse 5Ј-CCTCTGGGGTCCACACTTTA-3Ј; Prox1 forward 5Ј-AGAAGGGTTGACATTGGAGTGA-3Ј and reverse 5Ј-TGCGTGTTGCACCACAGAATA-3Ј; S26 forward5Ј-AAGTTTG TCATTCGGAACATT-3Ј and Reverse5Ј-GATCGATTCCTGACAAC CTTG-3Ј) using the 7300 Real-Time PCR System (Life Technologies) according to the manufacturer's instructions. Gene expression threshold-cycle values were normalized to endogenous levels of S26. Samples were run in triplicate and corresponded to three independent biological samples.
Construction of shRNA vectors and pCIG overexpression vectors. The pU6-Bclaf1 small hairpin RNA (shRNA) was generated by ligation of the following annealed oligonucleotides into the pGSU6 RNAi vector (Genlantis) according to the supplier's instructions: 5Ј-GatccGCAGCTTC CGGCGACATTTgaagcttgAAATGTCGCCGGAAGCTGCttttttggaagc-3Ј and 5Ј-ggccgcttccaaaaaaGCAGCTTCCGGCGACATTTcaagcttcAAATGTCG CCGGAAGCTGCg-3Ј. The GeneSilencer shRNA vector contain the U6 RNA polymerase III promoter, allowing optimal expression of shRNA and a GFP reporter gene under the control of CMV promoter. The ligation product was transformed into OneShot TOP10 chemically competent Escherichia coli cells (Life Technologies). Positive clones were identified by restriction enzymes analysis of purified plasmid and verified by DNA sequencing.
The rat Bclaf1 (NM_001047852) was cloned using the gateway technology (Life Technologies) into a pCIG-eGFP vector that contained an internal ribosome entry site sequence to generate enhanced green fluorescent protein (eGFP) under the control of the same ␤-actin promoter (Roger et al., 2006) . Specific primers with incorporated attB sites (available on request) were designed to amplify full-length of the Bclaf1, Bclaf1-DC210, and Bclaf1-DN384. The PCR reactions were performed with Platinium TaqDNA Polymerase High Fidelity (Life Technologies) using mice genomic DNA (or pCIG-Bclaf1-eGFP for mutant construction) as the template. The different specific PCR products purified after gel agarose electrophoresis were then subcloned into the entry clone (pDONR221 vector) by BP Clonase Reaction (Life Technologies). OneShot TOP10 chemically competent E.coli cells were transformed by using 5 l of the BP reaction. Positive clones were identified by restriction enzyme analysis of purified plasmid and verified by DNA sequencing. Each pDONR221-Bclaf1 construct was recombined in the presence of LR recombinase (Life Technologies) into a pCIG-eGFP gateway. OneShot TOP10 chemically competent E. coli cells were transformed and positive clones were identified by restriction enzyme analysis.
Western blot analysis. Protein extracts were collected in lysis buffer (20 mM NaH 2 PO 4 , 250 mM NaCl, 30 mM NaPPi, 0.1% NP40, 5 mM EDTA, 5 mM DTT) containing protease inhibitors from transfected DF1 fibroblast cells. Homogenates were sonicated and centrifuged for 5 min at 5000 g, and then 20 g of the supernatant were subjected to SDS-PAGE, as previously described (Roger et al., 2006) . Antibody binding was revealed by the Enhanced Chemiluminescence System Plus (GE Healthcare) on X-Ray film.
CAT assay. Baby hamster kidney (BHK)-21 cells, cultured as previously described (Planque et al., 2001 ), were seeded 24 h before transfection with polyethylenimine, Exgen 5000 (Euromedex) reagent according to the instructions of the manufacturer. Expression plasmids (900 ng) were cotransfected and the total amount of transfected DNA was kept constant by addition of empty expression vector. A pcDNA3-LacZ was cotransfected for normalization of CAT assays by controlling the galactosidase activity. CAT assays were performed as described previously (Planque et al., 2001 ). Levels of CAT activity were quantified after exposure of the thin layer chromatograms to a PhosphorImager screen (GE Healthcare).
Quantitative analysis. In the Bclaf1 Ϫ/Ϫ and wild-type (WT) mice, the number of cells expressing the different markers was quantified by averaging the total number of positive cells on three different retinal sections centered on the optic nerve. We examined retinas from at least three Bclaf1 Ϫ/Ϫ and control littermate mice. For quantification of dissociated cells that were immunolabeled as a monolayer, a minimum of 300 and up to 1000 cells per sample were counted using MetaMorph software (Universal Imaging). Quantification of marker staining is expressed as mean Ϯ SEM. Statistical analysis was performed using Prism 6 (Graph- Figure 1 . Characterization and expression pattern of Bclaf1 in the developing mouse retina. A, Retinal sections from E14.5 to adulthood mice were stained with a rabbit-polyclonal antibody against Bclaf1. Bclaf1 expression is restricted to the INBL and the GCL from E14.5 to P3 and then to the INL until adulthood. Note that at P3 and later, a few Bclaf1ϩ cells are also found in the differentiating ONL and could potentially correspond to horizontal cells. The white boxed areas on E14.5 panels are twofold magnifications (top and right corner) to show the faintly labeled cells located in the center of the retina. Scale bars: 60 m (E14.5), 30 m (E16.5-adulthood). IPL, Inner plexiform layer; OPL, outer plexiform layer. B, Schematic structure of short and long isoforms of Bclaf1. The black box corresponds to the deleted part in the short isoform of Bclaf1. The epitope recognized by the Bclaf1 polyclonal antibody maps to a region between residues 150 and 200, shared by the two isoforms. C, Expression of the long and short isoforms of Bclaf1 in the retina at E18.5, P3, and P14 detected by PCR using specific primers able to amplify both isoforms (primers a ϩ b) or only the short isoform (primers c ϩ b). 
Results

Bclaf1 is expressed in differentiating early-born Pax6-positive neurons in the retina
Spatiotemporal analysis of Bclaf1 expression by immunostaining revealed that Bclaf1 is present in the retina from E14.5 to adulthood (Fig. 1) . A clear expression was detected in the inner neuroblastic layer (INBL) at E16.5 (Fig. 1A) and also in the ganglion cell layer (GCL) at E18.5. From E18.5 to P3, Bclaf1 was expressed in the GCL and in the INBL that corresponds mainly to the differentiating inner nuclear layer (INL). At P3, a few sparsely labeled cells were also found in the differentiating outer nuclear layer (ONL; Fig. 1A ). At P7, Bclaf1 remained expressed in the GCL and INL and its expression was restricted to these two nuclear layers in adulthood (Fig. 1A) . Because both a short and long isoform of Bclaf1 have been described in human and mice tissue RT-PCR experiments were performed on mRNA extracts from mice retinas at several stages of development with primers specifically designed to discriminate the different Bclaf1 isoforms (Fig. 1B) . A set of primer (a and b) hybridizing on both sides of the region lacking in the short isoform (Fig. 1B) allowed the amplification of two fragments corresponding to the short and the long isoforms at E18.5, P3, and P14. (Fig. 1C) . The expression of the Bclaf1 short isoform was confirmed by defining a forward primer (c) that hybridized only with the cDNA sequence of this isoform ( Fig. 1 B, C) .
To identify the retinal cell types that express Bclaf1, a series of double immunostaining experiments were performed on retinal sections at different stages of development. During embryonic stages, Bclaf1 expression was restricted to postmitotic precursors that are both cyclinD1-negative ( Fig. 2A) and Pax6-positive (Fig.  2B) , including Brn3a-positive differentiating RGCs (Fig. 2C) . Conversely, Bclaf1 was not expressed by RXR␥-positive cells located in the upper part of the retina and corresponding to cone photoreceptor precursors (Fig. 2G ) and did not colocalize with markers of photoreceptor precursors, such as Otx2, Crx, and recoverin ( Fig. 2D-F) . From P0 to P5, Bclaf1 was still expressed by early-born retinal cells in the differentiating inner retina as identified by immunostaining for Pax6 (ACs, HCs, and RGCs; 
Delay and defect of early-born retinal cell differentiation in absence of Bclaf1
To understand the function of Bclaf1, we analyzed the retinal phenotype of Bclaf1-deficient (Bclaf1 Ϫ/Ϫ ) mice (McPherson et al., 2009 ). At E14.5, when Pax6 is expressed throughout the retina, the density of Pax6-positive cells showed no differences between Bclaf1 Ϫ/Ϫ and WT retinas (data not shown). However, at E16.5 and E18.5, when Pax6 expression is progressively restricted to postmitotic cells, we observed a reduction in the density of Pax6-positive cells in Bclaf1-deficient retina compared with WT retina (Fig. 4) . Consistent with the absence of expression of Bclaf1 in mitotic retinal progenitor cells, we did not observe any difference in the density of both CyclinD1-and PCNA-positive cells between WT and Bclaf1 Ϫ/Ϫ retina (Fig. 4 A, B) . Regarding lateborn cells, no differences were observed at E18.5 in the density of Otx2-positive precursors or differentiating photoreceptors (Crxor recoverin-positives) between Bclaf1 Ϫ/Ϫ and WT retina (Fig.  4) . Because Pax6 is expressed in differentiating RGCs, ACs, and HCs, quantitative analysis of these three populations was performed using specific markers (Fig. 5A-F ) . At E14.5, the density of Brn3a-positive RGCs was reduced by 55.9% in Bclaf1-deficient retina compared with WT retina (Fig. 5D) . At E16.5, the density of Brn3a-positive cells was still decreased in Bclaf1 Ϫ/Ϫ retina (minus 35.5%; Fig. 5 A, D) , whereas at E18.5 the difference between Bclaf1 Ϫ/Ϫ and WT retina was reduced to 14.4%, a statistically nonsignificant difference (Fig. 5D ). The density of ACs/HCs immunoreactive for Calbindin was not significantly modified at E16.5 (Fig. 5E ), but was significantly reduced in Bclaf1 Ϫ/Ϫ retina at E18.5 (Fig. 5 B, E) . Indeed, the density of calbindin-positive ACs (GCL/INBL) and calbindin-positive HCs [outer neuroblastic layer (ONBL)] was lower in E18.5 Bclaf1 Ϫ/Ϫ retina compared with WT: 88.5 Ϯ 10.4 cells/mm versus 119.5 Ϯ 10.7 cells/mm for ACs (n ϭ 3; p Ͻ 0.05) and 31.1 Ϯ 2.6 cells/mm versus 49.5 Ϯ 3.4 cells/mm for HCs (n ϭ 3; p Ͻ 0.05). Evaluation of apoptosis by TUNEL experiments in Bclaf1 Ϫ/Ϫ and WT showed the presence of rare positive cells at E14.5, E16.5, and E18.5 retinas with no difference between both genotypes (data not shown). This suggests that the reduced number of early-born cell types observed in Bclaf1 Ϫ/Ϫ retinas is not caused by an increase in cell death. Interestingly, RXR␥ immunostaining at E18.5 (Fig. 5C,F ) demonstrated that the density of cone photoreceptors, that do not express Bclaf1, was increased by twofold in Bclaf1 Ϫ/Ϫ retina (192 Ϯ 25.2 cells/mm) compared with WT retina (99 Ϯ 6.6 cells/ mm, n ϭ 3, p Ͻ 0.05).
As we observed that the impairment in RGC generation was resolved at E18.5 in Bclaf1 Ϫ/Ϫ retinas in situ, we questioned whether the defect observed in AC and HC generation at E18.5 in Bclaf1 Ϫ/Ϫ retinas could also be compensated at later stages. Bclaf1-deficient mice present a considerable perinatal mortality (McPherson et al., 2009 ). Accordingly we shifted to an ex vivo approach using retinal explant cultures (Roger et al., 2006; Lelièvre et al., 2012) . Retinas were explanted at E18.5 and analyzed by immunohistochemistry after 7 d in vitro (DIV). At this stage, the density of HCs (Lim1-positives) was 17.0% lower in Bclaf1 Ϫ/Ϫ retinal explants compared with WT explants (Fig.  5G,H ) . ACs (calretinin-positives) were also less numerous in Bclaf1 Ϫ/Ϫ retinal explants with a decrease in density of 31.4% (Fig. 5G,H ) . The density of Calbindin-positive cells, including both HCs and a subpopulation of ACs, was reduced by 17.6% in Bclaf1 Ϫ/Ϫ compared with WT retinas (Fig. 5G,H ) . At the same stage (E18.5 ϩ 7 DIV), immunostaining for arrestin revealed that the number of positive cells is increased by 35% in Bclaf1 Ϫ/Ϫ retinal explants compared with WT explants (Fig. 5G,H ) , confirming the increase of cone-photoreceptors density previously observed with RXR␥ labeling at E18.5 (Fig. 5C,F ) . The substantial cell death of RGCs found in retinal explants prevented us from analyzing this population.
Because we initially identified Bclaf1 from transcriptomic analyses during rat retinal development (Roger et al., 2007) , we next investigated whether the functional invalidation of Bclaf1 in rat embryonic retina could reproduce the retinal phenotype observed in Bclaf1 Ϫ/Ϫ mice. We first confirmed that the expression profile of Bclaf1 in the rat retina was indeed identical to that observed in the mouse retina (Fig. 6A) . Retinal explants from E16 rat embryos were electroporated with a pU6-shBclaf1-eGFP or a control pU6-shLuciferase-eGFP vector. Five DIV after electroporation, a significant decrease in Pax6-positive cells among the GFP-positive population was observed in shBclaf1-electroporated explants (35.2 Ϯ 1.4%) compared with shLuciferaseelectroporated control explants (47 Ϯ 3.6%; n ϭ 3, p Ͻ 0.05; Fig.  6 B, C) . Bclaf1 silencing decreased the number of GFP-positive ACs immunoreactive for AP2 or calretinin by 29.4 and 23.0%, respectively (Fig. 6 B, D) and the density of GFP-positive HCs immunoreactive for Lim1 by 24.3% (Fig. 6 B, E) . Calbindin immunostaining confirmed the reduction of both AC and HC number, whereas 6.1 ϩ 0.99% calbindin-positive cells was present in control only and 1.82 ϩ 0.48% remained after Bclaf1 silencing (Fig. 6B) . No significant difference in the number of apoptotic cells(TUNEL-positive)wasobservedbetweenshBclaf1-electroporated explants and control explants (Fig. 6B) , precluding the fact that cell death causes the decrease in different cell type numbers upon silencing of Bclaf1. These results were consistent with the data we observed in the Bclaf1 Ϫ/Ϫ mice and strongly confirmed a role for Bclaf1 in the differentiation of Pax6-positive early-born retinal cells.
Overexpression of Bclaf1 in late RPCs hinders the differentiation of rod photoreceptors but fails to promote early-born retinal cell fate
We next examined whether Bclaf1 overexpression in late RPCs, that do not normally express this factor, could modify their cell fate and promote their differentiation into neurons with an "early-born" phenotype. The effective expression of Bclaf1 cloned into a pCIG-eGFP (Roger et al., 2006) vector has been verified at the protein level by Western blotting in DF1 cells (see Fig. 8B ). After 7 DIV, overexpression of Bclaf1 led to 45.4% increase in the Pax6-positive fraction in dissociated cells from P0-electroporated explants (Fig. 7A) . However, quantification of the proportion of ACs and HCs identified with calretinin and calbindin revealed no significant changes following Bclaf1 overexpression (Fig. 7A) . As Bclaf1 seems unable to promote AC and HC differentiation, we next sought to determine the effect of forced Bclaf1 expression in the regulation of genes required for earlyborn AC and HC specification. q-PCR performed on mRNA extracts from FACS-isolated GFP-positive cells 36 h after electroporation revealed no changes in the mRNA expression of three transcription factors required for AC or HC specification (Dyer et al., 2003; Li et al., 2004; Fujitani et al., 2006) , notably Ptf1a, FoxN4, and Prox1 despite a sixfold increase in Bclaf1 expression (Fig. 7B ). This indicates that Bclaf1 does not act as a positive transcriptional regulator of genes required for AC/HC specification. Moreover, we also observed a significant decrease in the fraction of rhodopsin-positive photoreceptors in Bclaf1-electroporated explants (22.2 Ϯ 1.9%) compared with controls (50.1 Ϯ 1.9%; n ϭ 3; p Ͻ 0.01; Fig. 7C ). To test the possibility that forced Bclaf1 expression might induce rod apoptosis, TUNEL staining was performed. Despite a low number of positive cells, we observed a threefold increase in the number of TUNELpositive cells among the GFP-positive population in the ONL of explants overexpressing Bclaf1 as compared with control ex- 
7%, respectively) (E). The density of cone-photoreceptor precursors (RXR␥ϩ cells) is increased by 93% in Bclaf1
Ϫ/Ϫ compared with WT retina at E18.5 (F ). RXR␥ϩ cells were quantified in the ONBL only (dotted line delimited area) to exclude nonphotoreceptor RXR␥ϩ cells. G, Sections from retinal explants (E18.5 ϩ 7 DIV) of Bclaf1 Ϫ/Ϫ mice or WT littermate were stained for Lim1, calretinin, calbindin, or cone arrestin (green) and counterstained for DAPI (gray). H, The density of Lim1ϩ (HCs), calretininϩ (ACs), and calbindinϩ cells (HCs and ACs) at E18.5 ϩ 7 DIV was reduced in Bclaf1 Ϫ/Ϫ retinal explants compared with WT, whereas the density of CARϩ cells (cone photoreceptors) was higher. Error bars indicate SEM and an asterisk a significant statistical difference (*p Ͻ 0.05, **p Ͻ 0.01; n ϭ 4 -5). Scale bars, 30 m. plants (Fig. 7 D, E) . These results indicate that apoptosis of photoreceptor precursors or differentiating rods contribute to the decreased number of rods after Bclaf1 overexpression in late RPCs.
Molecular mechanisms underlying Bclaf1 effects
To further understand the molecular mechanisms underlying Bclaf1-mediated changes in retinal differentiation, we constructed two different mutants of Bclaf1: Bclaf1-DC210, a truncated form of Bclaf1 that is unable to interact with Bcl-2 proteins (Kasof et al., 1999) , and Bclaf1-DN384 which lacks the "SR richbZip domain" but is able to bind Bcl-2 proteins and Emerin (Kasof et al., 1999; Mansharamani and Wilson, 2005;  Fig. 8 A, B) . After fibroblast transfection, Western blot analysis with specific polyclonal antibodies against the C-terminal part or N-terminal part of Bclaf1 confirmed the production of the two mutant forms DC210 and DN384 at the predicted sizes of 25 and 54 kDa respectively (Fig. 8B) . Immunofluorescence experiments revealed that the DN384 mutant is located exclusively in the cytoplasm in contrast to the full-length form of Bclaf1 and the DC210 mutant which both display nuclear localization (Fig. 8C) . Electroporation of these mutants in P0 retinal explants revealed that only the overexpression of Bclaf1-DC210 led to the same effects as those observed after the overexpression of the full-length form of Bclaf1, i.e., an increase in the fraction of Pax6-positive cells and a decrease in the fraction of rhodopsin-positive cells (Fig. 8D) . These results indicate that the SR rich domain of Bclaf1 is required for its effects on retinal differentiation, independently of its interaction with endogenous Bcl-2-related proteins.
Bclaf1 expression pattern during development showed that this factor is preferentially localized in the nucleus of Pax6-positive cells (Figs. 2 B, E, 3) . Because leucine-zipper transcription factors such as MafA have been shown to modulate Pax6 transcriptional activity through their bZip domains (Kataoka et al., 2001; Planque et al., 2001) , we tested the effect of an enhancement of Pax6 transcriptional activity by Bclaf1 which carries a bZip domain. Cotransfection of the Pax6-dependent glucagon promoter (Planque et al., 2001) with vectors expressing Pax6 and Figure 6 . Bclaf1 silencing in early rat RPCs reproduces the retinal phenotype of Bclaf1-deficient mice. A, Rat retinal sections from the indicated developmental stages were immunolabeled with a Bclaf1 rabbit-polyclonal antibody (red) and weakly counterstained with nuclear DAPI (gray). Bclaf1 expression is restricted to the INBL and both the INL and GCL at different developmental stages. B-E, Retinal explants from E16 rats were electroporated with either pU6-shBclaf1-eGFP or pU6shLuciferase-eGFP (control) vectors. After 5 DIV, dissociated cells (B) or frozen sections (C-E) from retinal explants were double-immunostained with an anti-GFP antibody and antibodies against the indicated cell type. Silencing Bclaf1 led to a decrease in positive cells for Pax6, AP2, calretinin, Lim1, and calbindin among GFPϩ cells (B) . No differences in cell death were observed after silencing Bclaf1 compared with control (B). Sections stained for GFP and either Pax6 (C), calretinin (D), or Lim1 (E) showed a decrease in double-labeled cells in shBclaf1-electroporated explants. Arrows indicate colabeled cells. Values represent the mean Ϯ SEM (*p Ͻ 0.05, **p Ͻ 0.01) from at least three separate retina counts. Scale bar, 50 m.
Bclaf1 resulted in a threefold increase of promoter activity compared with the level of expression obtained with Pax6 alone (Fig.  8E) , whereas Bclaf1 alone did not activate the glucagon promoter. The Bclaf1-DC210 mutant form transactivated the glucagon promoter to a similar extent as the full-length Bclaf1, whereas the Bclaf1-DN384 mutant form lost its transactivation property (Fig.  8E) . Together, these findings indicate that Bclaf1 is able to enhance Pax6 transcriptional activity via its "SR rich-bZip domain." To support this potential role in the retinal context, we evaluated the expression level of three different Pax6 target genes (Marquardt et al., 2001; Shaham et al., 2012) in Bclaf1-deficient retina. q-PCR analysis on mRNA extracts from E16.5 retina revealed no significant change in the expression of Atoh7 but a reduced expression of Ascl1a and Ngn2 by 36% and 38%, respectively, in Bclaf1 Ϫ/Ϫ mice compared with WT littermates (Fig. 8F ) .
Discussion
Bclaf1 contributes to the differentiation of RGCs, ACs, and HCs
In the present study, we report that the transcription factor Bclaf1 is expressed in Pax6-positive early-born retinal cells and contributes to the differentiation process of RGCs, ACs, and HCs, independently of interactions with anti-apoptotic members of the Bcl-2 family. Analysis of the retinal phenotype of embryonic Bclaf1-deficient mice demonstrated a delay in the generation of RGCs, a defective generation of ACs and HCs, and a slightly higher density of cone photoreceptors. Silencing endogenous Bclaf1 expression by electroporation of a shRNA in embryonic retina confirmed that Bclaf1 plays a positive role during AC and HC generation. By contrast, Bclaf1 alone is unable to respecify late RPCs into an AC or HC lineage.
Because Bclaf1 expression begins at E14.5 and is restricted to postmitotic cells, it is unlikely that Bclaf1 could be involved in the fate commitment and initial generation of RGCs, whose specification is initiated earlier at ϳE11 in mice (Young, 1985; Yang et al., 2003; Bassett and Wallace, 2012) . However, Bclaf1 could potentially contribute to the RGC diversity programming like Brn3 genes (Badea et al., 2009) or to the terminal differentiation like Ils1 (Pan et al., 2008) , or more probably cooperate with these last genes to ensure proper differentiation of RGCs, as described for early B-cell factors (Jin et al., 2010) .The generation of RGCs was only delayed in absence of Bclaf1, because the density of RGCs at E18.5 is comparable in WT and Bclaf1 Ϫ/Ϫ retina, suggesting that, although dispensable, Bclaf1 contributes to the timing of the generation of the RGCs. The absence of Bclaf1 could be compensated by other factors, as previously demonstrated for transcription factors Sox11 and Sox4. Indeed, the generation of RGCs is delayed in Sox11-deficient mice but compensated for after birth possibly because of the redundant activity of Sox4 (Usui et al., 2013) .
Bclaf1 may play a more crucial role in the differentiation and maintenance of ACs and HCs. Indeed, a reduction of 15 and 30% in the numbers of ACs and HCs, respectively, was observed in the retinas of embryonic Bclaf1 Ϫ/Ϫ mice and no full compensation was present as far as we could measure. ACs and HCs are generated slightly later than RGCs (Livesey and Cepko, 2001) and be- cause in rodents, RPCs switch from early to late identity around birth, we can postulate that thereafter that they will no longer be able to generate enough ACs and HCs to counterbalance the late embryonic deficit in AC and HC generation. Forced expression of Bclaf1 in late RPCs is not sufficient to confer competence to generate early-born neurons like ACs and HCs, presumably because Bclaf1 is not able to induce the expression of genes required for AC and HC production (Dyer et al., 2003; Li et al., 2004; Fujitani et al., 2006) , as we demonstrated in the case of the transcription factors FoxN4, Ptf1, and Prox1. Because Bclaf1 is expressed by virtually all ACs, it seems unlikely that Bclaf1 contributes to the specification or the differentiation of a particular subtype of ACs in contrast to others factors such as Bhlb5 or Nr4a2, which contribute to the specification of GABAergic amacrine cells (Feng et al., 2006; Jiang and Xiang, 2009 ). The homeobox gene Barhl2, which is involved in the specification of glycinergic ACs, is expressed like Bclaf1 in postmitotic differentiating RGCs, ACs, and HCs (Mo et al., 2004) . However, in contrast to Bclaf1, forced expression of Barhl2 in late RPCs is able to promote the formation of glycinergic ACs at the expense of bipolar and Müller cells (Mo et al., 2004) . Nonetheless, forced Bclaf1 expression in postnatal retinal explants shifted the proportions of neuronal cell types generated with an increase in Pax6-positive cells and a reduction in rod photoreceptors. This may be a result of the forced re-expression of Pax6 in late RPCs, which normally give rise to rods, bipolar, and Müller cells, thus hijacking their original cell fate. However, the incapacity of Bclaf1 to readily confer competence to generate early-born neurons is inconsistent with this hypothesis. Alternatively, the increase in the Pax6-positive cell ratio could result from a specific cell death among the non-Pax6-expressing cells. The increase of apoptotic cell number specifically in the ONL after forced expression of Bclaf1 is in agreement with this hypothesis. Selective cell death of Bclaf1-expressing late RPCs and/or rod precursors could potentially ex- The black box corresponds to the sequence that is lacking in the short isoform. The gray boxes represent the putative bZip and Myb DNA binding domains. B, Expression of the two mutants of Bclaf1, cloned into pCIG-eGFP vector and transfected in DF1 cells. Western-blotting analysis confirmed the production of the two mutant forms DC210 and DN384 at the predicted sizes of 25 and 54 kDa, respectively. Polyclonal and monoclonal antibodies recognized epitopes corresponding to region from residues 150 -200 (full form and DC210; left) and 318 -439 (full form and DN384; right) respectively. C, Analysis of subcellular localization of the two Bclaf1 mutants in DF1 cells by immunofluorescence. Note that the DN384 mutant is located exclusively in the cytoplasm in contrast to the full-length form of Bclaf1 and the DC210 mutant, which both display nuclear localization. D, Retinal explants from P0 pups were electroporated with either pCIG-Bclaf1-eGFP, pCIG-DC210-eGFP, pCIG-DN384-eGFP or pCIG-eGFP (control) vectors. After 7 DIV, dissociated cells from retinal explants were double-immunostained with an anti-GFP antibody and antibodies against Pax6 or rhodospin. Only overexpression of DC210 mutant leads to the same effects that full-length form of Bclaf1. E, BHK21 cells were transiently transfected with a reporting vector driving expression of CAT under the control of the glucagon promoter (which is Pax6-dependent), the Pax6-expressing vector, and one of the vectors expressing the distinct mutants of Bclaf1. Bclaf1 alone is unable to transactivate the glucagon promoter but a synergistic effect on the transactivation of the glucagon promoter is observed between Pax6 and Bclaf1 when they are coexpressed, except in the case of the DN384 mutant. The results expressed as mean Ϯ SEM from at least three different experiments were normalized to ␤-galactosidase activity derived from a cotransfected CMV-LacZ expression plasmid. F, q-PCR on mRNA extracts from E16.5 retina showed that Ascl1a and Ngn2 relative expression was reduced in Bclaf1 Ϫ/Ϫ compared with WT embryos. No modification of expression was observed for the Atoh7 relative expression. Data are expressed as mean Ϯ SEM from three different experiments (*p Ͻ 0.05, ***p Ͻ 0.001).
plain the decrease in the proportion of rhodopsin-positive cells and the resulting increase in the proportion of Pax6-positive cells. In addition, it suggests that the survival of late-born cells is compromised by the ectopic expression of a factor specifically expressed in early-born cells.
Among the early-born cells, cone photoreceptors are unique in their lack of Bclaf1 expression. A higher density of differentiating cone photoreceptors (RXR␥-and cone arrestin-positive cells) is present in Bclaf1-deficient retinas thus suggesting that the absence of Bclaf1 may favor the differentiation into the cone lineage. On the other hand, Bclaf1 absence does not influence the generation of rod photoreceptors (Otx2-positives or Crxpositives) from late RPCs and therefore, it appears that the higher density of cone photoreceptors in Bclaf1 Ϫ/Ϫ retinas is specific to this cell type. Cone photoreceptors are generated earlier than rod photoreceptors and more or less in the same time window than ACs and HCs (Bassett and Wallace, 2012) . It was suggested that the cone lineage could be the default pathway for photoreceptor differentiation (Swaroop et al., 2010) . Some Bclaf1-deficient early-born cells may therefore switch from an AC/HC fate to a cone photoreceptor fate which may represent the only other fate alternative for cells that are being generated at that time. It is, unlikely that Bclaf1 participates directly in the specification and differentiation of cone photoreceptors, such as previously reported for specific nuclear receptors (Swaroop et al., 2010) and the transcription factor from the Spalt family, Sall3 (de Melo et al., 2011) . Our experimental data implicates Bclaf1 as a factor that is most likely helping early precursors to differentiate rather than as an instructive factor, such as Ptf1a (Fujitani et al., 2006; Lelièvre et al., 2011) .
Mechanisms of Bclaf1-mediated regulation of retinal development
Domain deletion analysis showed that truncation of the RS domain of Bclaf1 (Bclaf1-DN384) abolished its effect on RPC differentiation, whereas a Bclaf1 mutant with the C-terminal deletion (Bclaf1-DC210) retained most of its activity. Thus, the domain necessary for interaction with Bcl-2 is not required for Bclaf1 to exert its effects. This suggests that Bclaf1 plays a role independent of apoptosis during retinal development as previously reported for Bclaf1 in development (McPherson et al., 2009; Sarras et al., 2010) . Conversely, the N-terminal domain, which is sufficient to repress transcription (Kasof et al., 1999) and which contains both the RS and bZip domains, was essential for Bclaf1 function in the retina. RS-containing proteins are typically linked with pre mRNA biogenesis and processing events. Various studies have already identified Bclaf1 as an actor in processes governing RNA metabolism, such mRNA splicing and processing (Merz et al., 2007; Bracken et al., 2008; Sarras et al., 2010) . It is tempting to speculate whether the role of Bclaf1 in regulating mRNA processing events could explain its role in retinal development. Bclaf1 might also participate in the control of alternative splicing of bHLH transcription factors and/or the regulation of mRNA translation of retinal homeogenes, two processes that have been involved in retinal specification and differentiation (Decembrini et al., 2006) .
Another mechanism whereby Bclaf1 could mediate its effect is through its ability to enhance Pax6 transcriptional activity. We showed that Bclaf1 acts in synergy with Pax6 to activate the glucagon promoter. The presence of the bZip domain was necessary to mediate this effect in agreement with previous studies reporting that the domain spanning the basic region and the leucine zipper structure of other bZip factors is required for association with Hox proteins (Kataoka et al., 2001 ). In the developing retina, Bclaf1 and Pax6 expression patterns are very similar, suggesting that a functional synergy between Bclaf1 and Pax6 may occur in postmitotic precursors to facilitate their differentiation into ACs, HCs, or RGCs. The reduced expression of the two Pax6 target genes, Ascl1a and Ngn2, in E16.5 Bclaf1-deficient retina supports this hypothesis. Although the physical interaction between these two transcription factors remains to be established, functional synergy between Pax6 and Bclaf1 might also participate in the prevention of photoreceptor differentiation, because Pax6 has been identified as a potential repressor of Crx expression (OronKarni et al., 2008) . Furthermore, if Bclaf1 functions are dependent on Pax6, the absence of Pax6 expression in late RPCs could explain why Bclaf1 is unable to bias their commitment.
In conclusion, our results have shown that Bclaf1 contributes to the differentiation of early precursors into RGCs, ACs, and HCs instead of cone photoreceptors. Moreover, our data indicates that Bclaf1 participates in the differentiation process of RGCs, ACs, and HCs as a transcription factor, rather than via its interaction with Bcl-2-related proteins, and most probably by potentiating the activity of Pax6.
